Narcolepsy Drugs Market Report 2026

The narcolepsy drugs market size has grown strongly in recent years. It will grow from $3.94 billion in 2025 to $4.3 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to limited treatment options available, underdiagnosis of narcolepsy, dependence on stimulant medications, increasing awareness of sleep disorders, introduction of sodium oxybate.

The narcolepsy drugs market size is expected to see strong growth in the next few years. It will grow to $5.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising development of novel therapeutics, increasing investment in neurology research, growing demand for personalized medicine, expansion of extended-release formulations, increasing global narcolepsy diagnosis rates. Major trends in the forecast period include increasing adoption of novel wakefulness-promoting agents, growing use of combination therapy for symptom control, rising diagnosis rates due to improved awareness, expanding treatment options for cataplexy and eds, development of long-acting and extended-release drug formulations.

The growing demand for personalized medicine is expected to drive the expansion of the narcolepsy drugs market. Personalized medicine aims to tailor treatments to the specific needs of each patient, taking into account genetic profiles, symptom severity, metabolic rates, and personal preferences. This approach allows narcolepsy drugs to optimize effectiveness and minimize side effects. The demand for personalized medicine is rising due to advances in omics technologies, data integration, genetics, and the growing recognition of patient-specific therapies and preventive interventions. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from six in 2022. Therefore, the increasing demand for personalized medicine is fueling the growth of the narcolepsy drugs market.

Major companies in the narcolepsy drugs market are focusing on developing innovative products such as extended-release therapeutics to enhance treatment efficacy and patient experience. Extended-release (ER) therapeutics maintain stable drug levels, improve medication adherence, reduce side effects, and provide better symptom management for narcolepsy patients. For instance, in May 2023, Avadel Pharmaceuticals, an Ireland-based specialty pharmaceutical company, launched Lumryz, an extended-release sodium oxybate medication approved by the US FDA. Lumryz allows patients to maintain consistent therapeutic levels overnight with a single dose, simplifying treatment schedules, improving adherence, and enhancing overall quality of life compared to traditional multiple-dose regimens.

In October 2025, Viatris Inc., a US-based global healthcare company, acquired Aculys Pharma, Inc., a Japan-based clinical-stage biopharmaceutical company, for an undisclosed amount. This acquisition strengthens Viatris’ central nervous system (CNS) portfolio in Japan and key Asia-Pacific markets by adding development and commercialization rights to two innovative neurological assets, including pitolisant and Spydia (diazepam) nasal spray.

Major companies operating in the narcolepsy drugs market are Jazz Pharmaceuticals plc, Harmony Biosciences Holdings Inc, Avadel Pharmaceuticals plc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Axsome Therapeutics Inc, NLS Pharmaceutics Ltd, Alkermes plc, Bioprojet Pharma sarl, Arena Pharmaceuticals Inc, Novartis AG, Shionogi Inc, Rhodes Pharmaceuticals LP, Janssen Global Services LLC, Eli Lilly and Company, Centessa Pharmaceuticals UK Ltd, Azurity Pharmaceuticals Inc, Amneal Pharmaceuticals Inc, Hikma Pharmaceuticals plc, Sunovion Pharmaceuticals Inc, Addrenex Pharmaceuticals Inc, Graymark Healthcare Inc, Theranexus, Suven Life Sciences.

North America was the largest region in the narcolepsy drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the narcolepsy drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised production and distribution costs in the narcolepsy drugs market by increasing import duties on active pharmaceutical ingredients and finished drug formulations. Central nervous system stimulants, sodium oxybate, and antidepressant segments are particularly impacted, especially in regions dependent on offshore manufacturing such as the United States and Europe. These higher costs have led to pricing pressure across retail and hospital pharmacies. Positively, tariffs are encouraging regional drug manufacturing and API sourcing diversification.

The narcolepsy drugs market research report is one of a series of new reports that provides narcolepsy drugs market statistics, including narcolepsy drugs industry global market size, regional shares, competitors with a narcolepsy drugs market share, detailed narcolepsy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the narcolepsy drugs industry. This narcolepsy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Narcolepsy drugs are medications specifically developed to manage and relieve the symptoms of narcolepsy, a chronic neurological disorder marked by excessive daytime sleepiness (EDS), sudden episodes of muscle weakness or paralysis (cataplexy), sleep paralysis, and hallucinations. These medications are often used in combination and tailored to individual patient needs, aiming to enhance quality of life by reducing the severity of narcolepsy symptoms.

The main types of narcolepsy drugs correspond to narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Narcolepsy with cataplexy is characterized by sudden, temporary muscle weakness or paralysis triggered by strong emotions such as laughter, surprise, or anger. Treatments address conditions such as excessive daytime sleepiness and cataplexy, using therapeutics like sodium oxybate, central nervous system stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and other medications.

The narcolepsy drugs market consists of sales of orexin receptor antagonists, stimulants, and orexin-based therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.